The first report of in vivo gene delivery to the retina dates back to 1987 when a retroviral vector was injected intraocularly in newborn mice. Later came the observation that retinal cells could be successfully transduced using adenoviral and, then, adeno-associated and lentiviral vectors. By 2000, it had became clear that the eye, compared with other organs and tissues, provides a number of advantages for in vivo gene therapy with regard to safety, efficacy and route to clinical application. This has prompted the development of many successful proof-of-concept studies in animal models. The demonstration that sight could be restored in a large animal model with a congenital form of blindness was a major landmark that opened the door to the first-in-human trials for recessively inherited blinding conditions. With these first human studies demonstrating safety and some efficacy, retinal gene therapy has now come of age. The rapid clinical development of retinal gene therapy has highlighted various new challenges, such as management of inflammation and development of new vectors that allow optimization. The treatment of patients with advanced photoreceptor degeneration or dominantly inherited retinal dystrophies and the delivery of large genes, yet given the progress over the last 25 years, the next decade promises a bright future for retinal gene therapy.
Text
In 1987 the group of Connie Cepko used intraocular delivery of retroviral vectors to label rodent retinal cell progenitors with reporter genes. 1 Although it was not for therapeutic purposes, this study was the first report of in vivo gene delivery to the retina. In the last twenty five years, however, there has been a rapid expansion of ocular gene delivery for therapeutic purposes. There have been significant contributions from many different groups, many of them European. In 1994 the groups of Beverly Davidson 2 and Stephen Jones 3 observed efficient and effective delivery to retinal pigment epithelium (RPE) cells with an adenoviral vector. Efficient transduction of photoreceptors, the main target cells for gene therapy of inherited retinal degeneration, had to wait for the development of what has since become the most effective and widely used vector for retinal gene therapy, the adeno-associated viral vector (AAV). Subretinal administration of AAV serotype 2 in adult rodents resulted in efficient photoreceptor transduction in addition to RPE. 4, 5 Around the same time, administration of newly developed HIV1-based lentiviral vectors to the retina of newborn mice resulted in transduction of RPE and photoreceptor cells. 6 However, even in newborn animals the levels of photoreceptor transduction achieved did not reach the levels that could be achieved using AAV-based vectors, leaving the latter as the vector of choice for treating most retinal disorders. Subsequently, many more naturally occurring 7, 8, 9 or engineered 10, 11 AAV serotypes have been assessed for their ability to transduce the retina with the aim of identifying serotypes with advantageous properties: different cell tropisms, a greater ability to penetrate the inner retina or to mediate higher levels of transgene expression. In general, most AAV vectors are able to mediate efficient and life-long transduction of the neuroretina.
From these initial experiments with vectors encoding reporter genes it was apparent that the retina offered several advantages in terms of in vivo gene delivery when compared to other tissues. Whilst intraocular administrations are technically challenging, they allow precise exposure of the tissue to vector. The amount of vector required to obtain substantial retinal exposure is limited, minimizing both risks of toxicity and the challenge of large-scale viral vector production. The retina is relatively immune-privileged, and the presence of two eyes allows the delivery/treatment of one leaving the contralateral eye as an intra-individual control. Furthermore, a number of small and large animal models of inherited retinal diseases (IRDs) were available to test safety and efficacy of retinal gene therapy. These have been instrumental for the development of the many proof-of-concept studies that have been reported since the late 1990s. There are dozens of examples of rodent models in which retinal structure and function have been substantially improved by subretinal administration of viral vectors, most commonly AAV. 12 Perhaps the first clear proof-of-concept study was carried out by Robin Ali and colleagues who used subretinal delivery of an AAV2 vector to deliver a gene encoding the structural protein peripherin/rds to restore photoreceptor structure and function . 13 14 In the early 2000s, came the observation that efficacy of retinal gene therapy in small animals could be replicated in larger species. These studies not only demonstrated that scale-up of retinal gene therapy was feasible but also that restoration of vision was was evident by observing the behavior of treated animals, and thus even the lay public could appreciate the beneficial effect of retinal gene therapy in a visually impaired dogs. The pivotal study was performed by a group of US investigators, including Bill Hauswirth, Sam Jacobson and Gus Aguirre and co-ordinated by Jean Bennett. They demonstrated that a single subretinal administration of an AAV2 vector carrying an RPE65 gene resulted in long term restoration of night vision in Briard dogs affected by Leber congenital amaurosis type 2 (LCA2) caused by RPE65 deficiency. 15 In 2005 Hurwitz and colleagues treated retinoblastoma in children using intraocular injection of an adenoviral vector carrying a suicide gene. 16 The procedure was well tolerated, and in several cases resolution of the intravitreous tumor seeds was observed. This study represents the first example of an ocular gene therapy clinical trial involving a viral vector. It was soon followed by several other ocular gene therapy trials. The dramatic improvement in function obtained in the Briard dogs paved the way for the development of the first clinical trials of gene therapy for an inherited retinal dystrophy. In 2007-2008 there were three independent clinical trials of gene therapy for LCA2, involving subretinal administration of AAV2 vectors carrying RPE65. The trials, two in the US and one in the UK, showed that AAV-mediated gene therapy could be safe and effective, with improvements in visual acuity, pupillary reflex, light sensitivity and ability to navigate in dim light. 17, 18, 19 Therapeutic benefit was observed several weeks after injection and at least some benefit was observed in some individuals even 3 years after treatment. However, two of the trials, reported a decline in the level of visual improvement was not sustained long term 20, 21 highlighting the potential need for either higher levels of transgene expression or for a wider retinal transduction. This has prompted the development of a new trial for LCA2 using AAV5, a AAV serotype that provides a more efficient retinal transduction than AAV2, in combination with an optimized transgene expression cassette in order to provide higher levels of RPE65 (NTC02946879, Table I ). 22 At the same time a phase III clinical trial has been developed (NCT00999609, Table  I ) using an original AAV2 vector with the objective of collecting sufficient data to obtain market authorization. 23 Whatever, the eventual outcome of the current efforts to develop an effective gene therapy for LCA2, the positive results obtained by different groups has facilitated a rapid expansion in the number of clinical trials of gene therapy for other IRDs. These include conditions such as choroideremia, 24 Leber optic neuropathy, 25 or Stargardt disease, 26 among others (Table I ) and also common complex diseases, such as age-related macular degeneration (AMD) ( Table I) . 27, 28 The contribution of European academic groups and companies to the retinal gene therapy clinical trials has been substantial. In the UK, trials of therapies for LCA2 (NCT 00643747 and 02781480), X-linked RP (NCT03252847) and CNGB3 achromatopsia (NCT03001310) have been developed by UCL/Moorfields Eye Hospital and MeiraGTx; trials for chroideremia (NCT01461213) and X-linked RP (NCT03116113) by The University of Oxford and NightStarX and trials for Usher type 1B (NCT01505062), Stargardt disease (NCT01367444) and AMD (NCT01301443) by Oxford Biomedica. In France a trial for Leber hereditary optic neuropathy (NCT02064569) has been developed by the Institut de la Vision, and GenSight in Paris as well as a trial for LCA2 using AAV4 (NCT01496040) by The University of Nantes. In Germany, a trial for CNGA3 achromatopsia (NCT02610582) has been developed by groups at the University Hospital Tübingen and the Ludwig-Maximilians-University Munich. The rapid clinical development of gene therapy, including retinal gene therapy, suggests that the use of nucleic acids as drugs is finally coming of age. The multitude of trials, using various vectors, promoters, administration routes and doses will establish the basic toolkit for clinical gene therapy of the retina. Over the next couple of year, by assessing and comparing immune responses, vector shedding and effects of intraocular vector administration on retinal structure and function the safety and efficacy of particular vectors, routes of administration and doses will be determined. Whilst initial development in mice and dogs has provided a sound starting point for these trials, it is becoming increasingly clear that pre-clinical data alone does not necessarily enable effective translation of a protocol from animals to humans and for many therapies further optimization is likely to be required at the clinical trial stage.
As shown in Table I , the majority of the early trials have been in rare inherited disorders, but gene therapy can also be used for more common complex disorders. The condition most widely studied with regard to gene therapy has been neovascular AMD, since existing, but expensive pharmacological treatments had already validated VEGF as an effective target. 29 For that reason, the failure of the first anti-VEGF gene therapy using AAV-sFlt1 was a disappointment. 27 A positive outcome should have been achievable, but questionable clinical trial design and surgical issues have led to an ambiguous conclusion regarding therapeutic efficacy. This set back should not prevent further development of this area. The potential for major benefits to patients and socioeconomic benefits due to a single administration of a vector to target neovascularization versus repeated administration of a pharmacological agent has led to the development of various other anti-angiogenic gene therapy approaches and the initiation of a number of early phase clinical trials (table I) .(refs) 28, 30 Recent and ongoing retinal gene therapy trials are also highlighting some of the challenges that the field has to overcome to make this approach widely used. One is that subretinal administration of vector may induce irreversible damage to a tissue that has been thinned by many years of progressive degeneration. In this situation, less invasive intravitreal injections would be preferable. Yet the current generation of viral vectors do not cross the retinal layers from the vitreous to the photoreceptors. To solve this issue, the groups of Schaffer and Flannery set up a strategy based on in vivo directed evolution of libraries of thousands of AAV capsid variants that were administered to the vitreous of mice. The variants able to cross the retinal layers from the vitreous were isolated from photoreceptors. Enrichment in one variant, AAV7M8, occurred through repeated cycles of intravitreal injections, followed by photoreceptor harvesting and AAV capsid sequence isolation. 10, 31 As a result, AAV7M8 shows unprecedented ability to transduce mouse outer retina from the vitreous. 31 Confirming this ability in retinas of larger species with thicker physical barriers than mice is ongoing and the first results look promising. 32 AAV7M8, or other variants with similar properties 33, 34 may one day allow to avoid subretinal injection of therapeutic viral vectors in patients with IRDs.
One particular challenge to achieving a substantial clinical impact in the field of retinal gene therapy is the large number of genes involved in IRDs (https://sph.uth.edu/retnet/). Development of a generic gene therapy for photoreceptor cell loss has thus been a longstanding goal. Animal studies have shown that gene transfer of neurotrophic molecules, including CNTF, 35 GDNF 36,37 and bFGF, 38 or anti-apoptotic proteins, such as XIAP, 39 to the retina can prolong the photoreceptor cell survival although this does not always lead to preservation of remaining vision. 40 To date there have been no clinical trials of neurotrophic or anti-apoptotic gene therapy, perhaps because implantation of encapsulated cells secreting CNTF directly into the vitreous showed a more pronounced loss of light sensitivity in the treated eye, that reversed after removal of the implant. No long-term evidence of improved vision or preserved retinal structure was found. 41 One-third of RP patients with a recognizable pattern of inheritance are affected by dominant RP of which many are due to toxic gain-of-function mutations (https://sph.uth.edu/retnet/). Among these are RHO P23H and P347S mutations for which there are useful transgenic mouse models 42, 43 . Reducing levels of the toxic product rather than adding a correct copy of the gene is expected to provide significant benefits. The first attempts in this direction used allelespecific ribozymes to knock-down RHO P23H expression. 44 The discovery of RNA interference in mammalian cells led to the development by the group of Jane Farrar, Trinity College Dublin, and others of AAV-delivered short hairpin RNAs (shRNAs) which would knock-down both the wild-type and mutant RHO allele coupled with replacement of a RHO cDNA resistant to the shRNA. 45 A different approach tuses artificial transcriptional repressors developed in the lab of Enrico M. Surace that silence RHO expression, again in an allele-independent manner thus requiring supply of a RHO copy that is resistant to silencing. 46 Although pre-clinical results are promising and there are efforts to further develop these strategies into the clinic, one has to consider that knocking down RHO expression might convert a mild dominant RP into more severe recessive conditions that require expression of high levels of rhodopsin, the most abundant protein in photoreceptors.
The last decade has also witnessed the development of new tools for genome editing that allow efficient engineering of genes in situ. Among these tools are Znfinger (ZF) nucleases, TALE nucleases and, more recently, those based on the CRISPR-associated RNA-guided Cas9. 47 Each of these systems allows precise induction of double strand breaks at specific genomic loci that can be repaired either by non-homologous end-joining, potentially knocking out specific dominant mutant alleles or by homology-directed repair that corrects the gene defect using a donor DNA template. The versatility and efficacy of these systems has increased over the years to levels that now reach therapeutic efficacy in the retina of animal models. 48 However, off-target mutagenesis and the effects of prolonged expression of nucleases to terminally differentiated photoreceptors need to be carefully evaluated before clinical application.
For a substantial group of IRD patients the 'standard' gene therapy protocols described above will not be feasible. They are the advanced cases where most if not all photoreceptors have been lost to the degenerative process. Optogenetics may offer an alternative therapeutic strategy to regenerative medicine for those severely damaged retinas with no remaining photoreceptors. Gene transfer of bacterial opsins, 49, 50 or even rhodopsin, 51 to post-photoreceptor neurons like bipolar or retinal ganglion cells has the potential to convert them in light sensing neurons. Although a clinical trial of optogenetic gene therapy is being prepared based on Channelrhodopsin2, the current generation of halorhodopsins or channelrhodopsins still requires abnormally high light intensities to be effectively excited. 52, 53 The optogenetics field however is constantly developing. Improvement of optogenetic tools for ocular therapeutics can be achieved by engineering of the channels to display optimised characteristics. Channel engineering has been used previously to improve their function as neuroscientific tools, e.g. sacrificing light sensitivity to achieve faster channel kinetics. 54 For therapeutic use, such fast kinetics are not necessary and a channel with kinetics equivalent to or somewhat slower than cone phototransduction, is likely to display better light sensitivity. Moreover, using different vector serotypes it may be possible to transduce bipolar cells rather than ganglion cells and achieve more advanced intraretinal processing.
One important limitation of AAV vectors, which to date are the most effective platform for gene delivery to photoreceptor cells, are their cargo capacity that is limited to around 5 kb of DNA. This prevents their application to gene therapy of common and severe IRDs like Stargardt disease, Usher IB or LCA10 which are due to mutations in genes with a coding sequence larger than 5 kb. 
